Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033548 · ClinicalTrials.gov registry record
Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient
A clinical trial, sponsored by CareDx.
- Terminated
- Registry status
- 246
- Enrollment target
NCT05033548: Clinical Trial study, sponsored by CareDx.
NCT05033548 is a clinical trial that was terminated before completion, run by CareDx. The registered enrollment target is 246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05033548 was terminated before completion, sponsored by CareDx.
- TERMINATED
- Registry status
- 246 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the impact of AlloCare mHealth remote monitoring on the early post-transplant period in solid organ transplantation.The outcome measure for primary objective is overall reduction in Readmission Rate to hospital in 90 days for all causes. Patients will be assessed across 4 different organ groups (Kidney, Liver, Lung and Heart Transplantation). The secondary objective is to consider the impact of mHealth and app-based monitoring on variables known to impact long term outcomes over the first 12 months post transplantation, as well as impact on quality of life. The outcome measures for secondary objective are: 1. Tacrolimus Variability (Time in Therapeutic Range,) as a surrogate to adherence and compliance 2. BPAR within 3,6, and 12 months 3. Patient satisfaction at 90 days 4. SF-36 change at 90 days 5. HbA1c monitoring (diabetic patients only)
Primary Outcome
The aim of this study is to evaluate AlloCare and remote patient monitoring developed as an integrated mHealth service, assessing whether the combination of app and monitoring deployed within the solid organ transplant population can help support durable behavioral changes in patients that improve self-care and shared decision-making within the patient-provider relationship.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2023-07-31 |
Why NCT05033548 stopped before completion
NCT05033548 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05033548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05033548 about?
NCT05033548 is a clinical study titled "Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient". The primary objective of the study is to assess the impact of AlloCare mHealth remote monitoring on the early post-transplant period in solid organ transplantation.The outcome measure for primary objective is overall reduction in Readmission Rate to hospital in 90 days for all causes. Patients will ...
What is the current status of trial NCT05033548?
This trial is currently terminated. The enrollment target is 246 participants. The study started on 2021-10-26. Estimated completion is 2023-07-31.
Who is sponsoring clinical trial NCT05033548?
This trial is sponsored by CareDx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI